Open November ’12

Title: A randomised double-blind study of Denosumab V’s Zoledronic Acid (Zometa) in the treatment of bone disease in patients with Newly Diagnosed Multiple Myeloma.

Population: Patients with newly diagnosed MM who are for first line treatment and who have never received previous Intravenous biphosphonate treatment.

Resource Links

« Back